Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Ruiz, I, Perelló, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Máhr, K, Schenker, M, Sohn, J, Lee, KS, Shepherd, CJ, Oelmann, E, Sarker, S-J, Prendergast, A, Marosics, P, Moosa, A, Lawrence, C, Coetzee, C, Mousa, K and Cortés, J (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5 (11). 1556 - 1556.

[img]
Preview
Text
M Brunt - Fulvestrant plus vistusertib vs fulvestrant plus....pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (401kB) | Preview
Item Type: Article
Additional Information: This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2019 Schmid P et al. JAMA Oncology.
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > Institute for Science and Technology in Medicine
Depositing User: Symplectic
Date Deposited: 25 Nov 2019 15:13
Last Modified: 25 Nov 2019 15:13
URI: https://eprints.keele.ac.uk/id/eprint/7295

Actions (login required)

View Item View Item